{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:59:38Z","timestamp":1785527978398,"version":"3.56.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>While use of factor Xa inhibitors has increased, there are relatively few cases of overdose reported. Clinically relevant bleeding is often absent, and the behavior of drug levels in overdose is not fully agreed on.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Report<\/jats:title>\n                    <jats:p>A 70-year-old male presented after a polysubstance overdose including at least 250 mg of apixaban with massive gastrointestinal (GI) hemorrhage and parafalcine and tentorial subdural hematoma. He was treated with 1 gram tranexamic acid (TXA), anti-inhibitor coagulant complex (FEIBA), and massive transfusion. No further episodes of bleeding were observed. Anti-Xa levels were trended until undetectable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Bleeding from an overdose of factor Xa inhibitors is a relatively rare occurrence; however, this case illustrates that life threatening hemorrhage can occur and may require aggressive supportive care. Anti-Xa levels demonstrated a first order pattern of elimination even at markedly supratherapeutic concentrations, consistent with several prior case reports.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s13181-026-01137-5","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T20:18:44Z","timestamp":1776111524000},"page":"392-397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Apixaban Overdose with Massive Bleeding and Anti-Xa Levels"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5331-5119","authenticated-orcid":false,"given":"Rebecca","family":"Kusko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jami","family":"Hagemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Trebach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"issue":"6","key":"1137_CR1","doi-asserted-by":"publisher","first-page":"e13746","DOI":"10.1111\/eci.13746","volume":"52","author":"M Delrue","year":"2022","unstructured":"Delrue M, Chevillard L, St\u00e9panian A, Dragoni A, Camoin-Jau L, Voicu S, Malissin I, Deye N, Gainnier M, Siguret V, M\u00e9garbane B. Case series of massive direct oral anticoagulant ingestion-Treatment and pharmacokinetics data. Eur J Clin Invest. 2022;52(6):e13746. https:\/\/doi.org\/10.1111\/eci.13746.","journal-title":"Eur J Clin Invest"},{"key":"1137_CR2","unstructured":"Apixaban Assay (Anti Xa). In: UIDL Test Directory. University of Iowa Diagnostic Laboratories. 2025. www.healthcare.uiowa.edu\/path_handbook\/rhandbook\/test3593.html. Accessed 9 Mar 2026."},{"issue":"23","key":"1137_CR3","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1093\/ajhp\/zxad215","volume":"80","author":"D Jenniches","year":"2023","unstructured":"Jenniches D, Kerns AF, DelBianco J, Stripp MP, Philp AS. Administration of andexanet alfa for traumatic intracranial hemorrhage in the setting of massive apixaban overdose: A case report. Am J Health Syst Pharm. 2023;80(23):1722\u20138. https:\/\/doi.org\/10.1093\/ajhp\/zxad215.","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"1137_CR4","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1007\/s00414-023-03073-3","volume":"137","author":"P Kintz","year":"2023","unstructured":"Kintz P, Allain C, Oertel L, Feisthauer E, Ameline A, Raul JS. Complete investigations (autopsy, toxicology, and histology) in a death due to apixaban overdose. Int J Legal Med. 2023;137(6):1743\u201350. https:\/\/doi.org\/10.1007\/s00414-023-03073-3.","journal-title":"Int J Legal Med"},{"issue":"11","key":"1137_CR5","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1160\/TH17-07-0474","volume":"117","author":"L Mast","year":"2017","unstructured":"Mast L, Verheul RJ, Reijnen R, van Rossen RCJM, Overdiek JWPM, Wilms EB. Apixaban Auto-intoxication: Toxicokinetics and Coagulation Tests. Thromb Haemost. 2017;117(11):2209\u201311. https:\/\/doi.org\/10.1160\/TH17-07-0474.","journal-title":"Thromb Haemost"},{"issue":"1","key":"1137_CR6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/bcp.13790","volume":"85","author":"B Franck","year":"2019","unstructured":"Franck B, Dulaurent S, El Balkhi S, Monchaud C, Picard N, Couderc S, Marquet P, Saint-Marcoux F, Woillard JB. Self-poisoning with 60 tablets of Apixaban, a pharmacokinetics case report. Br J Clin Pharmacol. 2019;85(1):270\u20132. https:\/\/doi.org\/10.1111\/bcp.13790.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1137_CR7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1177\/08971900231177570","volume":"37","author":"E Harmouche","year":"2024","unstructured":"Harmouche E, Stueve P, Howland MA, Su MK. Massive Apixaban Overdose Confirmed with Blood Concentrations and Managed Without Bleeding: A Single Case Report. J Pharm Pract. 2024;37(3):761\u20135. https:\/\/doi.org\/10.1177\/08971900231177570.","journal-title":"J Pharm Pract"},{"issue":"9","key":"1137_CR8","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/15563650.2016.1204453","volume":"54","author":"J Barton","year":"2016","unstructured":"Barton J, Wong A, Graudins A. Anti-Xa activity in apixaban overdose: a case report. Clin Toxicol (Phila). 2016;54(9):871\u20133. https:\/\/doi.org\/10.1080\/15563650.2016.1204453.","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"1137_CR9","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1186\/s12887-020-02448-4","volume":"20","author":"M Launay","year":"2020","unstructured":"Launay M, Nasser Y, Maubert I, Chaux AC, Delavenne X. Accidental apixaban intoxication in a 23-month-old child: a case report. BMC Pediatr. 2020;20(1):546. https:\/\/doi.org\/10.1186\/s12887-020-02448-4.","journal-title":"BMC Pediatr"},{"issue":"2","key":"1137_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/MBC.0000000000000706","volume":"29","author":"DS Guadarrama","year":"2018","unstructured":"Guadarrama DS, DeMarinis SM, Sweeney JD. Coagulation assays in a case of apixaban overdose. Blood Coagul Fibrinolysis. 2018;29(2):231\u20135. https:\/\/doi.org\/10.1097\/MBC.0000000000000706.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"5","key":"1137_CR11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.ajem.2016.11.035","volume":"35","author":"SM Leikin","year":"2017","unstructured":"Leikin SM, Patel H, Welker KL, Leikin JB. The X factor: Lack of bleeding after an acute apixaban overdose. Am J Emerg Med. 2017;35(5):801. https:\/\/doi.org\/10.1016\/j.ajem.2016.11.035.e5-801.e6.","journal-title":"Am J Emerg Med"},{"issue":"5","key":"1137_CR12","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.ajem.2017.09.035","volume":"36","author":"J Ilicki","year":"2018","unstructured":"Ilicki J, H\u00f6jer J, Dj\u00e4rv T. Massive apixaban overdose - A comparison of three cases. Am J Emerg Med. 2018;36(5):891\u20133. https:\/\/doi.org\/10.1016\/j.ajem.2017.09.035.","journal-title":"Am J Emerg Med"},{"key":"1137_CR13","doi-asserted-by":"publisher","unstructured":"Crawley RM, Sheikh-Taha M. Comparison of activated and 4-factor prothrombin complex concentrates for reversal of apixaban- and rivaroxaban-associated major bleeding. J Thromb Thrombolysis. 2026 Jan;12. https:\/\/doi.org\/10.1007\/s11239-025-03232-w. Epub ahead of print.","DOI":"10.1007\/s11239-025-03232-w"},{"issue":"5","key":"1137_CR14","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","volume":"76","author":"GF Tomaselli","year":"2020","unstructured":"Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Gluckman TJ, Hucker WJ, Mehran R, Mess\u00e9 SR, Perino AC, Rodriguez F, Sarode R, Siegal DM, Wiggins BS. 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76(5):594\u2013622. https:\/\/doi.org\/10.1016\/j.jacc.2020.04.053.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1137_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.chest.2016.08.1462","volume":"151","author":"BT Samuelson","year":"2017","unstructured":"Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review. Chest. 2017;151(1):127\u201338. https:\/\/doi.org\/10.1016\/j.chest.2016.08.1462.","journal-title":"Chest"},{"issue":"3","key":"1137_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1055\/s-0038-1627480","volume":"118","author":"RC Gosselin","year":"2018","unstructured":"Gosselin RC, Adcock DM, Bates SM, Douxfils J, Favaloro EJ, Gouin-Thibault I, Guillermo C, Kawai Y, Lindhoff-Last E, Kitchen S. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost. 2018;118(3):437\u201350. https:\/\/doi.org\/10.1055\/s-0038-1627480.","journal-title":"Thromb Haemost"},{"key":"1137_CR17","unstructured":"Eliquis (Apixaban) package insert. Pfizer. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/220073s000lbl.pdf. Accessed 4 Dec 2025."}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-026-01137-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13181-026-01137-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-026-01137-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:16:24Z","timestamp":1785521784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13181-026-01137-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1137"],"URL":"https:\/\/doi.org\/10.1007\/s13181-026-01137-5","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Author RK owns stock in Pfizer.","order":1,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author JH, author DM, author JT declare that they have no conflict of interest.","order":2,"name":"Ethics","label":"Competing Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent for publication of this case was obtained and provided to the journal in accordance with JMT policy.","order":3,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}